drugset / Trial / NCT04008251
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Phase 1
Unknown
10 enrolled
Wuhan Sian Medical Technology Co., Ltd
Jingzhou Central Hospital · collabPeople Hospital Of Yichang · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabXiangyang Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label study to evaluate the safety and efficacy of humanized anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.
Timeline
- Start
- 2019-05-27
- Primary completion
- 2022-07-01
- Completion
- 2022-12-31
Publications
- Du M, Mayombo RTM, Liu J, Zhang Y, Liao D, Hu Y, Mei H. The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies. Ann Hematol. 2025 Mar;104(3):1887-1895. doi: 10.1007/s00277-025-06338-6. Epub 2025 Apr 8.
- Zhang Y, Zhou F, Wu Z, Li Y, Li C, Du M, Luo W, Kou H, Lu C, Mei H. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. Front Immunol. 2022 Jun 21;13:914959. doi: 10.3389/fimmu.2022.914959. eCollection 2022.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Second generation humanized CAR-T cells | Cell therapy | — | — |